glp-1 liver fibrosis Resmetirom and agonists for MASH: complementary rather than exclusive GLP-1 RAs for Treating Metabolic

regulators have not provided comments on whether the FDA is reviewing the issue

Gastroparesis patients endure persistent nausea, severe abdominal cramping, repeated vomiting episodes disrupting daily activities, and malnutrition from inability to properly digest food

57 , 140 , 161 In the absence of gastric ultrasound assessments, patients taking long-acting GLP-1 RAs within 4 weeks should be considered as having full stomachs and the anaesthetic plan, including proceeding with elective procedures, should be tailored accordingly

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study